
Objectives To systematically evaluate the analytical performance of 10 newly developed Mindray concentrated biochemical reagents (alanine aminotransferase concentrated reagent; ALTn, aspartate aminotransferase concentrated reagent; ASTn, albumin concentrated reagent; ALBn, total protein concentrated reagent; TPn, total bilirubin concentrated reagent; TBILn, direct bilirubin concentrated reagent; DBILn, glucose concentrated reagent; GLUn, carbon dioxide concentrated reagent; CO 2 n, urea concentrated reagent; UREAn, uric acid concentrated reagent; UAn) for routine clinical application in medium and large hospitals. Methods Method comparison was conducted in three clinical laboratories, while repeatability, precision, linearity, LoD, and onboard stability were evaluated at a single center Fu Xing Hospital, Capital Medical University (FXH-CMU (Fuxing Hospital, Capital Medical University). Method comparison was performed vs. Mindray non-concentrated, Roche, and Abbott reagents (per CLSI (Clinical and Laboratory Standards Institute) EP09-A3c). Results All 10 concentrated reagents exhibited excellent analytical performance: within-laboratory precision CV % ranged from 0.45 % to 3.00 %, with repeatability CV % below 2 %; all showed excellent linearity within clinically relevant concentration ranges, with R 2 (coefficient of determination) all exceeding 0.999. Limit of detection (LoD) values were lower than the claimed linear lower limits, and limit of blank (LoB) values were lower than LoD, meeting EP17-A2 requirements. method comparison revealed good agreement with all comparison systems: Passing-Bablok regression slopes were between 0.95 and 1.05, correlation coefficients (r) >0.995, mean biases at medical decision levels did not exceed ±4 %, and over 95 % of samples fell within Bland-Altman limits of agreement. CO 2 n, TPn, and UREAn maintained stable performance for 24 consecutive days after opening under standard instrument conditions (20–25 °C, 40–60 % humidity) without recalibration, with relative deviations ≤±4 %. Conclusions The newly developed Mindray concentrated reagents demonstrate excellent performance, meet laboratory quality requirements, reduce reagent replacement frequency, improve testing efficiency, and are well-suited for routine laboratory testing in medium and large hospitals.
Abstract Objectives To describe implementation of an automated plasma phosphorylated tau 217 (pTau217) reagent in a laboratory-defined workflow and evaluate concordance with cerebrospinal fluid (CSF) amyloid status. Methods We analyzed 73 matched CSF-plasma pairs from a memory-clinic cohort using CSF Aβ42/40 as reference. Published thresholds defined three classification zones. Renal analyses within this plasma-only cohort were exploratory and included amyloid-status adjustment. Analytical observations comprised one plasma dilution series, single-sample stability testing, and serum/CSF precision data. Results Plasma pTau217 discriminated CSF Aβ-positive status with an area under the curve (AUC) of 0.918 (95 % CI 0.825–0.987). Exploratory AUC estimates were 0.957 (95 % CI 0.889–0.999) for estimated glomerular filtration rate (eGFR) ≥60 and 0.692 (95 % CI 0.250–1.000) for eGFR <60 mL/min/1.73 m 2 . The latter subgroup comprised 13 Aβ-positive and four Aβ-negative patients; no formal AUC comparison was performed. At the rule-out threshold, 25/73 patients were classified as negative, including two Aβ-positive cases (negative predictive value 0.920). The rule-in zone comprised 39/73 patients, including three Aβ-negative cases (positive predictive value 0.923); nine patients (12.3 %) were intermediate. Conclusions Plasma pTau217 showed strong concordance with CSF Aβ42/40 status and potential for three-zone triage in memory-clinic patients. Exploratory renal findings warrant confirmation in larger cohorts.
Abstract Autoimmune encephalitides are rare, antibody-defined and treatable, and commercial assays have moved their diagnosis from specialised research laboratories into routine practice. Over 11 years in our laboratory the number of antibody analyses rose tenfold and the number of analytes per patient rose by 40 %. The proportion of patients with a positive result nevertheless remained near 6 %. The additional analytes identified no additional patients, and the already low pre-test probability per analyte has fallen further. Written for the laboratory, this review aims to provide practical guidance on raising the overall specificity and predictive value of the final report. It sets out what each assay format can and cannot do, which specimen to trust for which antibody, when a titre carries information, how to handle a result that only one technique supports, and which sample belongs in a referral laboratory. It also covers preanalytics, reader competence, external quality assessment and the regulatory framework for in-house assays. In general, the predictive value of a positive result is set not by the specificity of a single assay but by the whole pathway: serum and cerebrospinal fluid (CSF) read together, positives confirmed by a second technique, discordant findings referred rather than reported, and every result matched against the clinical syndrome. We propose graded levels of diagnostic certainty for common result constellations. In the future, reliable neuronal antibody diagnostics will depend less on new antigens than on disciplined reporting: internal training, consensus reading, quality control and dialogue with the requesting clinician.
Objectives: In this study, the first commercially available CE-certified test kit for the determination of ethyl glucuronide (EtG) in hair (EUREKA - Lab Division, Chiaravalle, Italy) known to us was evaluated. The aim was to assess the analytical performance of the assay with regard to clinical and forensic applications. The results provide a basis for evaluating the kit's suitability for routine laboratory use and for the objective assessment of long-term alcohol consumption in sensitive clinical and legal decision-making processes. Methods: 50 mg of ground hair is used for analysis. An isotopically labeled internal standard is added for later quantification. After extraction, 10 & micro;l aliquot of the resulting solution is injected into the LC-MS/MS system. The injection interval is 7.5 min. For the measurement an QTRAP 6500+ tandem mass spectrometer (AB Sciex, Darmstadt, Germany) and an Agilent UHPLC system (Waldbronn, Germany) were used. The method was validated according to the guidelines of the GTFCh directive. Results: The limit of detection of the commercial EtG test kit was 1.6 pg/mg hair. Intra-assay and inter-assay coefficients of variation were determined to be <9.2 %. Participation in interlaboratory proficiency tests was successful in all cases. A correlation of r=0.98 was observed between the commercial test kit and an established LC-MS/MS method. Conclusions: The commercial test kit is suitable for quantifying EtG in hair in order to estimate alcohol consumption or provide evidence of abstinence, in accordance with CTU criteria for participants undergoing driving aptitude assessments.
Objectives Blood-based biomarkers play a crucial role in tumor monitoring. However, for nasopharyngeal carcinoma with recurrence or metastasis (R/M-NPC), there is a notable scarcity of sensitive markers. Citrullinated histone H3 (H3Cit), a key marker of neutrophil extracellular traps (NETs), has been associated with the progression of various tumors. Nevertheless, its specific relationship with R/M-NPC remains poorly understood. Our study was designed to assess the potential of H3Cit as a predictor for R/M-NPC. Methods We recruited a cohort of 144 NPC patients, among which 80 (55.6 %) experienced recurrence or metastasis, while 64 (44.4 %) did not. Univariate and multivariate logistic regression analyses were employed to identify prognostic factors. H3Cit levels were measured, and a nomogram was developed by integrating H3Cit with other biomarkers. The nomogram was then validated in an independent cohort of 44 patients. Internal validation of the nomogram was performed using bootstrap resampling, and external validation was carried out in the independent cohort. Results Our analyses identified H3Cit (p<0.001, OR=4.706, 95 % CI=1.973-11.225), Lym (p=0.016, OR=0.355, 95 % CI=0.153-0.824), and FT4 (p=0.007, OR=0.228, 95 % CI=0.078-0.669) as independent prognostic factors. The calibration curves indicated excellent consistency. The C - index of the nomogram was 0.789 in the training cohort and 0.787 in the external validation cohort. The area under the curve (AUC) of the receiver operating characteristic curves (ROC) was 0.777 (p<0.001) in the training cohort and 0.787 (p=0.004) in the external validation cohort. The decision curve analysis demonstrated that the model had remarkable performance in clinical applications. Conclusions H3Cit emerges as a promising biomarker for predicting metastasis and recurrence in NPC patients. The nomogram constructed based on H3Cit and other factors exhibits high accuracy and strong clinical applicability in the early identification of R/M-NPC patients, which can contribute to timely and effective treatment strategies.